Remaxol

01/01/2022 - "The use of remaxol in patients with acute peritonitis complicated by peritonitis who have undergone open surgical interventions, due to the relatively rapid restoration of the functional status of the intestine and liver, reduction of catabolic phenomena, reduces the severity of endogenous intoxication syndrome, which was the basis for a significant improvement in the course of the early postoperative period, bringing it closer to that when using laparoscopic technology. "
01/01/2019 - "Remaxol include leads to a significant reduction in the severity of intoxication syndrome in patients with acute peritonitis. "
01/01/2019 - "The aim - of the study was to study the effectiveness of Remaxol in the correction of homeostasis disorders in patients with acute peritonitis after laparotomic surgery intervention. "
01/01/2019 - "The purpose of the study is to establish the effectiveness of remaxol in the correction of endogenous intoxication in patients with acute peritonitis. "
01/01/2016 - "The purpose of the research was to study the effectiveness of enteral insufficiency correction at an acute peritonitis by applying minimally invasive techniques, electrical stimulation and rehabilitation of the bowel and abdominal intestine using Remaxol drug. "

01/01/2012 - "The use of remaxol also greatly increased the absorptive and digestive activity of the peritoneal macrophages phagocytosis, inhibited in the process of the experimental tuberculosis development."
01/01/2012 - "[Investigation of remaxol efficacy in complex therapy of experimental generalized tuberculosis on mice]."
01/01/2012 - "The test agents (reamberine, remaxol, and ademethionine) are effective in treating tuberculosis patients with drug-induced liver injury. "
01/01/2012 - "[Effectiveness of the hepatoprotective activity of reamberine, remaxol, and ademethionine and risk assessment in their use in patients with respiratory tuberculosis and drug-induced liver injury]."
01/01/2013 - "[Comparative efficacy of clinical use of reamberin, remaxol and ademethionine in patients with tuberculosis of the respiratory organs and liver drug-injury]."

01/01/2013 - "[The efficacy of hepatotropic agent Remaxol in oncological patients with postoperative liver dysfunction]."
01/01/2013 - "The study of the efficiency and safety of the hepatotropic drug Remaxol in oncological patients with minimal, subclinical manifestations of liver dysfunction in the postoperative period was performed. "
01/01/2015 - "The obtained data on clinical and laboratory efficacy along with good drug tolerance allow us to recommend the inclusion of remaxol in the scheme of treatment for patients with acute and chronic liver disease."
12/15/2021 - "Remaxol at a dose of 400 ml/day demonstrates similar efficacy to Heptral at a dose of 800 mg/day in patients with intrahepatic cholestasis syndrome associated with chronic diffuse liver diseases. "
01/01/2010 - "This milticentre randomized clinical study of the efficiency of remaxol infusion solution (hepatoprotective medicine for chronic liver dysfunction) included 494 patients with chronic hepatitis B and C. "

01/01/2012 - "The comparative evaluation of the inclusion of heptral and remaxol in the treatment has shown that remaxol improves the clinical course of mentioned disorders decreasing the frequency and duration of alcohol delirium. "
01/01/2013 - "It was shown that remaxol reduced severity of metabolic disorders associated with hypoxic conditions and active lipid peroxidation and thereby decreased the frequency of alcoholic delirium to 10.8% (n=7) compared with ademetionine (10.8%, n=22). "
06/01/2012 - "In the process of a comparative valuation of the using of heptral (ademethionin) and remaxol in the intensive therapy of alcohol poisonings it has been revealed that the using of remaxol led to improvement of the clinic of that poisonings, what had been registered as a decrease of frequency and duration of an alcohol delirium from 33,9% to 10,8%, a decrease of frequency of secondary lung complication from 18,5 to 3,1%, a decrease of a duration of treatment in intensive care unit from 7,3 +/- 0,6 to 5,6 +/- 0,3 and a hospital treatment duration from 11,8 +/- 0,5 to 9,0 +/- 0,3 days. "
01/01/2012 - "Results of examination and treatment of 130 patients with severe alcoholic intoxication and toxic hepatopathy in conjunction with metabolic disorders are presented Inclusion of remaxol in therapy of alcoholic intoxication improved its clinical course (reduction in the frequency of secondary pulmonary complications from 18.5 to 3. 1%, the frequency and duration of alcoholic delirium from 33.9 to 10.8%, the duration of stay in an intensive therapy ward from 7.3+/-0.6 to 5.6+/-0.3 days and the overall duration of therapy from11.8+/-1.05 to 5.6+/-0.3 days). "
04/01/2012 - "Inclusion in the intensive care infusion hepatoprotector remaxol compared with ademetionine leads to a faster dynamics of improvement of the patients condition, evaluated by the scale assessing the severity APACHE II. Also found, Use of remaxol can reduce development of complications such is alcoholic delirium on the background of long-term abuse of alcohol in percentage from 31.9% to 16%, as well as reduces the time of stay of patients in the departments of the resuscitation and intensive care unit from 7,3±0,6 to 5,6±0,3 days and duration of treatment of patients in the hospital from 11,8±1,1 to 9,0±0,4 days."

01/01/2012 - "The comparative evaluation of the inclusion of heptral and remaxol in the treatment has shown that remaxol improves the clinical course of mentioned disorders decreasing the frequency and duration of alcohol delirium. "
01/01/2016 - "Period of using remaxol there was improvement in the clinical course of the disease, which manifested by the reduce the incidence of delirium tremens and shorten the duration of treatment of patients."
01/01/2012 - "Results of examination and treatment of 130 patients with severe alcoholic intoxication and toxic hepatopathy in conjunction with metabolic disorders are presented Inclusion of remaxol in therapy of alcoholic intoxication improved its clinical course (reduction in the frequency of secondary pulmonary complications from 18.5 to 3. 1%, the frequency and duration of alcoholic delirium from 33.9 to 10.8%, the duration of stay in an intensive therapy ward from 7.3+/-0.6 to 5.6+/-0.3 days and the overall duration of therapy from11.8+/-1.05 to 5.6+/-0.3 days). "